Ipca Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 8, 2025, 2:50 am

Competitors of Ipca Laboratories Ltd

All Competitor Stocks of Ipca Laboratories Ltd

Quarterly Result

Last Updated: August 20, 2025, 8:55 am

Below is a detailed analysis of the quarterly data for Ipca Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 2,309.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,247.00 Cr. (Mar 2025) to 2,309.00 Cr., marking an increase of 62.00 Cr..
• For Expenses, as of Jun 2025, the value is 1,892.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,818.00 Cr. (Mar 2025) to 1,892.00 Cr., marking an increase of 74.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 416.00 Cr.. The value appears to be declining and may need further review. It has decreased from 429.00 Cr. (Mar 2025) to 416.00 Cr., marking a decrease of 13.00 Cr..
• For OPM %, as of Jun 2025, the value is 18.00%. The value appears to be declining and may need further review. It has decreased from 19.00% (Mar 2025) to 18.00%, marking a decrease of 1.00%.
• For Other Income, as of Jun 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from -179.00 Cr. (Mar 2025) to 33.00 Cr., marking an increase of 212.00 Cr..
• For Interest, as of Jun 2025, the value is 19.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.00 Cr. (Mar 2025) to 19.00 Cr., marking a decrease of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 100.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 100.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 331.00 Cr.. The value appears strong and on an upward trend. It has increased from 128.00 Cr. (Mar 2025) to 331.00 Cr., marking an increase of 203.00 Cr..
• For Tax %, as of Jun 2025, the value is 29.00%. The value appears to be improving (decreasing) as expected. It has decreased from 49.00% (Mar 2025) to 29.00%, marking a decrease of 20.00%.
• For Net Profit, as of Jun 2025, the value is 233.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 233.00 Cr., marking an increase of 169.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 9.19. The value appears strong and on an upward trend. It has increased from 2.67 (Mar 2025) to 9.19, marking an increase of 6.52.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:06 am

Growth

Last Updated: September 5, 2025, 7:50 am

Balance Sheet

Last Updated: July 25, 2025, 2:59 pm

Below is a detailed analysis of the balance sheet data for Ipca Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
• For Reserves, as of Mar 2025, the value is 6,923.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,307.00 Cr. (Mar 2024) to 6,923.00 Cr., marking an increase of 616.00 Cr..
• For Borrowings, as of Mar 2025, the value is 1,363.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,438.00 Cr. (Mar 2024) to 1,363.00 Cr., marking a decrease of 75.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 3,432.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,326.00 Cr. (Mar 2024) to 3,432.00 Cr., marking an increase of 106.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 11,744.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 11,097.00 Cr. (Mar 2024) to 11,744.00 Cr., marking an increase of 647.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 4,267.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,554.00 Cr. (Mar 2024) to 4,267.00 Cr., marking a decrease of 287.00 Cr..
• For CWIP, as of Mar 2025, the value is 622.00 Cr.. The value appears strong and on an upward trend. It has increased from 343.00 Cr. (Mar 2024) to 622.00 Cr., marking an increase of 279.00 Cr..
• For Investments, as of Mar 2025, the value is 980.00 Cr.. The value appears strong and on an upward trend. It has increased from 862.00 Cr. (Mar 2024) to 980.00 Cr., marking an increase of 118.00 Cr..
• For Other Assets, as of Mar 2025, the value is 5,875.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,339.00 Cr. (Mar 2024) to 5,875.00 Cr., marking an increase of 536.00 Cr..
• For Total Assets, as of Mar 2025, the value is 11,744.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,097.00 Cr. (Mar 2024) to 11,744.00 Cr., marking an increase of 647.00 Cr..

Notably, the Reserves (6,923.00 Cr.) exceed the Borrowings (1,363.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Ipca Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 35.14. This value is within the healthy range. It has increased from 25.82 (Mar 24) to 35.14, marking an increase of 9.32.
• For Diluted EPS (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
• For Cash EPS (Rs.), as of Mar 25, the value is 46.72. This value is within the healthy range. It has increased from 34.94 (Mar 24) to 46.72, marking an increase of 11.78.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 273.88. It has decreased from 304.57 (Mar 24) to 273.88, marking a decrease of 30.69.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 352.37. It has increased from 303.71 (Mar 24) to 352.37, marking an increase of 48.66.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 71.70. This value is within the healthy range. It has increased from 56.99 (Mar 24) to 71.70, marking an increase of 14.71.
• For PBIT / Share (Rs.), as of Mar 25, the value is 56.02. This value is within the healthy range. It has increased from 42.91 (Mar 24) to 56.02, marking an increase of 13.11.
• For PBT / Share (Rs.), as of Mar 25, the value is 44.59. This value is within the healthy range. It has increased from 33.22 (Mar 24) to 44.59, marking an increase of 11.37.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 31.04. This value is within the healthy range. It has increased from 20.86 (Mar 24) to 31.04, marking an increase of 10.18.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 29.08. This value is within the healthy range. It has increased from 21.57 (Mar 24) to 29.08, marking an increase of 7.51.
• For PBDIT Margin (%), as of Mar 25, the value is 20.34. This value is within the healthy range. It has increased from 18.76 (Mar 24) to 20.34, marking an increase of 1.58.
• For PBIT Margin (%), as of Mar 25, the value is 15.89. This value is within the healthy range. It has increased from 14.12 (Mar 24) to 15.89, marking an increase of 1.77.
• For PBT Margin (%), as of Mar 25, the value is 12.65. This value is within the healthy range. It has increased from 10.93 (Mar 24) to 12.65, marking an increase of 1.72.
• For Net Profit Margin (%), as of Mar 25, the value is 8.80. This value is within the healthy range. It has increased from 6.86 (Mar 24) to 8.80, marking an increase of 1.94.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.25. This value is within the healthy range. It has increased from 7.10 (Mar 24) to 8.25, marking an increase of 1.15.
• For Return on Networth / Equity (%), as of Mar 25, the value is 10.61. This value is below the healthy minimum of 15. It has increased from 8.64 (Mar 24) to 10.61, marking an increase of 1.97.
• For Return on Capital Employeed (%), as of Mar 25, the value is 15.15. This value is within the healthy range. It has increased from 12.44 (Mar 24) to 15.15, marking an increase of 2.71.
• For Return On Assets (%), as of Mar 25, the value is 6.27. This value is within the healthy range. It has increased from 4.93 (Mar 24) to 6.27, marking an increase of 1.34.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.07, marking a decrease of 0.02.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has decreased from 0.21 (Mar 24) to 0.18, marking a decrease of 0.03.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.78. There is no change compared to the previous period (Mar 24) which recorded 0.78.
• For Current Ratio (X), as of Mar 25, the value is 2.63. This value is within the healthy range. It has increased from 2.35 (Mar 24) to 2.63, marking an increase of 0.28.
• For Quick Ratio (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has increased from 1.30 (Mar 24) to 1.55, marking an increase of 0.25.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.55. This value is below the healthy minimum of 4. It has increased from 1.05 (Mar 24) to 3.55, marking an increase of 2.50.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 13.75. This value is below the healthy minimum of 20. It has increased from 9.27 (Mar 24) to 13.75, marking an increase of 4.48.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.93. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 24) to 8.93, marking an increase of 3.33.
• For Earning Retention Ratio (%), as of Mar 25, the value is 86.25. This value exceeds the healthy maximum of 70. It has decreased from 90.73 (Mar 24) to 86.25, marking a decrease of 4.48.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.07. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 24) to 91.07, marking a decrease of 3.33.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 21.42. This value is within the healthy range. It has increased from 10.46 (Mar 24) to 21.42, marking an increase of 10.96.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.69. This value is within the healthy range. It has increased from 5.61 (Mar 24) to 12.69, marking an increase of 7.08.
• For Enterprise Value (Cr.), as of Mar 25, the value is 40,485.27. It has increased from 33,899.87 (Mar 24) to 40,485.27, marking an increase of 6,585.40.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.53. This value exceeds the healthy maximum of 3. It has increased from 4.40 (Mar 24) to 4.53, marking an increase of 0.13.
• For EV / EBITDA (X), as of Mar 25, the value is 22.26. This value exceeds the healthy maximum of 15. It has decreased from 23.45 (Mar 24) to 22.26, marking a decrease of 1.19.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
• For Retention Ratios (%), as of Mar 25, the value is 86.24. This value exceeds the healthy maximum of 70. It has decreased from 90.72 (Mar 24) to 86.24, marking a decrease of 4.48.
• For Price / BV (X), as of Mar 25, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.96 (Mar 24) to 5.48, marking an increase of 0.52.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.26. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 24) to 4.26, marking an increase of 0.18.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness